UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000007982
Receipt No. R000009397
Scientific Title A verification study to investigate the drug interaction via CYP3A between oral Midazolam administration and miltiple Anchusan dose in Janaese male subjects.
Date of disclosure of the study information 2012/05/25
Last modified on 2016/04/09

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A verification study to investigate the drug interaction via CYP3A between oral Midazolam administration and miltiple Anchusan dose in Janaese male subjects.
Acronym Drug interaction study between Midazolam and Anchu-san.
Scientific Title A verification study to investigate the drug interaction via CYP3A between oral Midazolam administration and miltiple Anchusan dose in Janaese male subjects.
Scientific Title:Acronym Drug interaction study between Midazolam and Anchu-san.
Region
Japan

Condition
Condition Japanese healthy male
Classification by specialty
Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 The pilot study that previously conducted (UMIN ID:000006655) suggested that 7 days oral Anchu-san administration would affect on PK of oral Midazolam dose. Therefore the verification study will be conducted with increased number of study subjects. This is a verification study to investigate the effects of the 6 days Anchu-san multiple dose (7.5/day) on the pharmacokinetics of oral administration of midazolam (7.5mg) in Japanese healthy male subjects.
The pharmacodynamic interaction between midazolam and Anchu-san will also be investigated.
Basic objectives2 PK,PD
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2 Explanatory
Developmental phase Not applicable

Assessment
Primary outcomes The pharmacokinetic parameters of midazolam in serum (AUC 0-10, Cmax, t1/2, tmax).
Key secondary outcomes The sedative action after midazolam oral administration: VAS
Safety assessment (pulse oximeter, vital measurement, adverse event)

Base
Study type Interventional

Study design
Basic design Cross-over
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control No treatment
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Prevention
Type of intervention
Medicine
Interventions/Control_1 Midazolam single oral administration
Interventions/Control_2 Midazolam single oral administration after 6 days Anchu-san (7.5g/day) dose
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
45 years-old >
Gender Male
Key inclusion criteria 1) Age: 20 - 45 years old at the time of informed consent
2)Sex: male
3) Subjects are competent to consent, keep the rules of the study and are able to report self condition.
4) Subjects who are judged eligible by the investigator in several series of medical check conducted prior to study.
Key exclusion criteria 1) Subjects who have an inappropriate clinical history for efficacy and safety assessment in the study (such as drug abuse, alcoholism, and the disease of heart, liver, kidney, lungs, eye, blood etc) and who is taking any drugs (including health supplements).
2) Any history for drug allergy
3) Subjects who are taking in too much alcohol (those who cannot maintain the abstains from alcohol during study period)
4) Subjects within three months after the participation to other clinical trials
5) Subjects who are inadequate for enrollment judged by the investigator.
Target sample size 6

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Naoki Uchida MD, PhD
Organization Showa University School of Medicine
Division name Department of Clinical Pharmacology
Zip code
Address 1-5-8 Hatanodai Shinagawa-ku Tokyo 142-8555
TEL 03-3784-8128
Email nuchida@med.showa-u.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Hirokazu Toshima MD
Organization Showa University School of Medicine
Division name Department of Clinical Pharmacology
Zip code
Address 1-5-8 Hatanodai Shinagawa-ku Tokyo 142-8555
TEL 03-3784-8128
Homepage URL
Email showa_northern@yahoo.co.jp

Sponsor
Institute Showa University School of Medicine Department of Clinical Pharmacology
Institute
Department

Funding Source
Organization None
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 昭和大学臨床薬理研究センター(東京都)
Showa University Clinical Trial Center for Clinical Pharmacology (Tokyo)

Other administrative information
Date of disclosure of the study information
2012 Year 05 Month 25 Day

Related information
URL releasing protocol
Publication of results Published

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
This study was performed in 7 subjects. No adverse event was observed during the study in all subjects. 
Mean value of PK parameter of plasma Midazolam are as follows; 

Pre-dose of Anchu-san
Cmax:64.99+/-18.61ng/mL, AUC:192.59+/-78.13ng*hr/mL

After 7 days Anchu-san dose
Cmax:88.66+/-16.37ng/mL, AUC:249.06+/-72.84ng*hr/mL

No difference was observed in VAS scale between pre- and post- Anchu-san dose. 

It was suggested that 7 days oral Anchu-san administration would affect on PK of oral Midazolam dose.

J. Showa Med Assoc.(in print)
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2012 Year 05 Month 25 Day
Date of IRB
Anticipated trial start date
2012 Year 07 Month 01 Day
Last follow-up date
2012 Year 09 Month 01 Day
Date of closure to data entry
2012 Year 11 Month 01 Day
Date trial data considered complete
2012 Year 11 Month 01 Day
Date analysis concluded
2012 Year 11 Month 01 Day

Other
Other related information

Management information
Registered date
2012 Year 05 Month 18 Day
Last modified on
2016 Year 04 Month 09 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009397

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.